Amlexanox Research Guide

Full name: Amlexanox (TBK1/IKKε Inhibitor)

An anti-inflammatory compound that inhibits TBK1 and IKKε kinases, enzymes that create obesity-driven insulin resistance. Emerging in telemedicine for metabolic syndrome and stubborn weight loss.

How Amlexanox Works

Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity.

Dosing Protocol

• Typical dose: 25-100 mg
• Frequency: 3x daily
• Duration: 8-12 weeks
• Route: Oral tablet

Reported Benefits

• Increased energy expenditure
• Improved insulin sensitivity
• Weight loss
• Reduced inflammation
• Metabolic reset

Potential Side Effects

• GI upset
• Diarrhea
• Headache
• Dizziness
• Mouth irritation

Research Citations

1. Amlexanox in obese type 2 diabetes (2021) - Improved insulin sensitivity by 25% and increased resting energy expenditure in 12-week randomized trial.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Amlexanox profile with 3D molecule viewer →